UNSPSC 51342709: Interferon beta-1a

This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XRO4566Q4R. European Medicines Agency schedules Interferon alfa-n1 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12440MIG. As of Q4 2014, INTERFERON BETA-1A remains the US FDA Preferred Term for this commodity. Interferon beta-1a bears US NLM identifiers UMLS ID C0982234 and NCI Concept Code C1823. SMILES: NONE.

UNSPSC 51342709 Interferon beta-1a is a Commodity code that nominally covers a specific immunomodulatory pharmaceutical used in multiple sclerosis treatment, but recent state and local solicitation activity shows minimal alignment with this code's stated scope. The two opportunities tagged under this code involve unrelated pharmaceutical products: antibiotics (Doxycycline and Ciprofloxacin) procured by Illinois and opioid-reversal agents plus drug deactivation systems procured by Seminole County, Florida. Neither opportunity involves interferon beta-1a or medications within its therapeutic class, suggesting either systematic miscoding in the opportunities database or that this code is being used as a catch-all for diverse pharmaceutical procurement rather than as a precision taxonomy marker.

Issuing bodies soliciting under this code include state health departments and county public health agencies. Illinois Department of Public Health awarded a completed piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, totaling $2.999999 million over 12 months with renewal options for years 2 and 3; Seminole County, Florida released an IFB on June 30, 2026 seeking annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, response due July 26, 2023. The geographic spread is limited to Florida and Illinois in the recent record. The mismatch between the code's nominal scope and the actual products being purchased signals that this code may not be a reliable filter for interferon beta-1a opportunities or for related biologics procurement in state and local markets.